Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
15 Results Found
AHA Letter to HRSA Re: The 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.
AHA Comments on DHS Proposed H-1B Visa Weighted Selection Process
The American Hospital Association comments on the Department of Homeland Security’s proposed weighted selection process for registrants and petitioners seeking to file cap-subject H-1B petitions.
AHA, Health Associations Comment on HRSA Notice of a 340B Rebate Model Pilot Program
AHA, health associations initial comment on the Health Resources and Services Administration’s (HRSA) notice of a 340B Rebate Model Pilot Program.
AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
AHA Urges Senate to Amend Budget Reconciliation Bill to Protect Access to Care
AHA shares very serious concerns with the amendment in the nature of a substitute for the One Big Beautiful Bill Act (OBBBA) (H.R. 1) that is being considered by the Senate.
AHA Comments on HHS RFI on MAHA Initiative
AHA comments on the U.S. Department of Health and Human Services request for information to ensure lawful regulation and unleash innovation to promote better health.
AHA Comments to HRSA on Proposed 340B Rebate Model Pilot Program
AHA comments on the Health Resources and Services Administration’s notice of the 340B Rebate Model Pilot Program.
UPDATE: Product Allocations for U.S. IV Products – Hurricane Impact on Baxter’s North Cove, NC Facility
A follow-up to Baxter’s communication on December 13, 2024 regarding increases in allocations for several U.S. IV products,
AHA Response to OMB Deregulation RFI
AHA responds to the Office of Management and Budget Deregulation Request for Information.